Compounds > telmisartan
Page last updated: 2024-08-24

telmisartan and Pulmonary Disease, Chronic Obstructive

telmisartan has been researched along with Pulmonary Disease, Chronic Obstructive in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's0 (0.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Hasan, SS; Kow, CS1
Bolotova, EV; Pavlishchuk, SA; Porkhanov, VA1

Other Studies

2 other study(ies) available for telmisartan and Pulmonary Disease, Chronic Obstructive

ArticleYear
The Potential Benefit of Telmisartan to Protect Overweight Patients with COPD from the Acquisition of COVID-19.
    Obesity (Silver Spring, Md.), 2020, Volume: 28, Issue:11

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Betacoronavirus; Coronavirus Infections; COVID-19; Female; Humans; Male; Mice; Overweight; Pandemics; Pneumonia, Viral; Pulmonary Disease, Chronic Obstructive; Rats; SARS-CoV-2; Telmisartan

2020
[Efficacy of telmisartan in chronic obstructive lung disease wtih arterial hypertension].
    Klinicheskaia meditsina, 2005, Volume: 83, Issue:7

    Topics: Aged; Airway Resistance; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Blood Pressure; Circadian Rhythm; Dose-Response Relationship, Drug; Forced Expiratory Flow Rates; Humans; Hypertension; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Telmisartan; Treatment Outcome

2005